Literature DB >> 9973477

Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax.

E J Goetzl1, Y Kong, B Mei.   

Abstract

Members of a subfamily of G protein-coupled receptors (GPCRs), encoded by five different endothelial differentiation genes (edgs), specifically mediate effects of lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) on cellular proliferation and differentiation. Mechanisms of suppression of apoptosis by LPA and S1P were studied in the Tsup-1 cultured line of human T lymphoblastoma cells, which express Edg-2 and Edg-4 GPCRs for LPA and Edg-3 and Edg-5 GPCRs for S1P. At 10-10 M to 10-7 M, both LPA and S1P protected Tsup-1 cells from apoptosis induced by Abs to Fas, CD2, and CD3 plus CD28 in combination. Apoptosis elicited by C6 ceramide was inhibited by S1P, but not by LPA, in part because ceramide suppressed expression of Edg-2 and Edg-4 surface receptors for LPA without affecting Edg-3 surface receptors for S1P. At 10-9 M to 10-7 M, LPA and S1P significantly suppressed cellular levels of the apoptosis-promoting protein Bax, without altering the levels of Bcl-xL or Bcl-2 assessed by Western blots and immunoassays. Transfections of pairs of antisense plasmids for Edg-2 plus Edg-4 and Edg-3 plus Edg-5, and hygromycin selection of transfectants with reduced expression of the respective Edg R proteins in Western blots, inhibited both protection from apoptosis and reduction in cellular levels of Bax by LPA and S1P. Thus, LPA and S1P protection from apoptosis is mediated by distinct Edg GPCRs and may involve novel effects on Bax regulatory protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973477

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.

Authors:  Irina V Tiper; James E East; Priyanka B Subrahmanyam; Tonya J Webb
Journal:  Pathog Dis       Date:  2016-06-27       Impact factor: 3.166

5.  Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.

Authors:  Whitney S McDonald; Elizabeth E Jones; Jonathan M Wojciak; Richard R Drake; Roger A Sabbadini; Neil G Harris
Journal:  Am J Pathol       Date:  2018-07-16       Impact factor: 4.307

Review 6.  Never say die: survival signaling in large granular lymphocyte leukemia.

Authors:  Mithun Vinod Shah; Ranran Zhang; Thomas P Loughran
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 7.  Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system.

Authors:  Edward J Goetzl; Wengang Wang; Christine McGiffert; Mei-Chuan Huang; Markus H Gräler
Journal:  J Cell Biochem       Date:  2004-08-15       Impact factor: 4.429

Review 8.  Heterotrimeric G proteins and apoptosis: intersecting signaling pathways leading to context dependent phenotypes.

Authors:  Vijay Yanamadala; Hideyuki Negoro; Bradley M Denker
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

Review 9.  Sphingosine 1-phosphate as a novel immune regulator of dendritic cells.

Authors:  Angelo Martino
Journal:  J Biosci       Date:  2007-09       Impact factor: 1.826

Review 10.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.